NCT06377982

Brief Summary

A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1

Timeline
32mo left

Started Sep 2025

Typical duration for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Sep 2025Dec 2028

First Submitted

Initial submission to the registry

April 17, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 22, 2024

Completed
1.4 years until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

February 27, 2025

Status Verified

February 1, 2025

Enrollment Period

2 years

First QC Date

April 17, 2024

Last Update Submit

February 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • safety-TEAE

    Frequency and incidence of treatment-emergent adverse events (TEAEs).

    From screening to 56 weeks

Study Arms (2)

hUCB treatment

EXPERIMENTAL

Human cord blood infusion

Biological: hUCB

Placebo treatment

NO INTERVENTION

Placebo infusion

Interventions

hUCBBIOLOGICAL

hUCB

hUCB treatment

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Male or female underage at the time of screening.
  • With a confirmed diagnosis of CP
  • non-progressive motor disability
  • brain dysfunction

You may not qualify if:

  • Judged by the Investigator to be not suitable/eligible for study participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cerebral Palsy

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Central Study Contacts

Ying Chieh Bobo Chen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2024

First Posted

April 22, 2024

Study Start

September 1, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2028

Last Updated

February 27, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share